Scholarlink

<p>Macrophage polarization has been known as a critical step in balancing inflammatory responses by creating a balanced plasticity between M1 and M2 macrophages, which act as pro-inflammatory and anti-inflammatory mediators, respectively. Histone deacetylases (HDACs) have been shown to play a vital role in polarization, identifying them as possible contributors and therapeutic targets in metabolic diseases, cancer, inflammatory diseases, and other associated conditions. In this regard, isoform-specific HDAC inhibitors (HDACis) can selectively alter macrophage polarization, thereby overcoming the limitations of pan-HDAC inhibitors and offering therapeutic advantages. Moreover, combining HDAC inhibitors with other therapies has emerged as a promising approach, especially in cancer; however, further studies should determine the specificity of HDAC inhibitors as well as address possible problems in optimizing the bioavailability and reducing off-target effects and cytotoxicity to translate these results into practical therapeutic plans for disorders associated with inflammation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epigenetic programming of macrophages across inflammatory and malignant diseases

  • 期刊论文

  • 发表日期：

    2025年11月25日

查看全文
  • Suleiman Ibrahim Mohammad,
  • Hamza Abu Owida,
  • Asokan Vasudevan,
  • Suhas Ballal,
  • Nawaf Alshdaifat,
  • Ali Akberzeda,
  • Abhayveer Singh,
  • Kavitha V.,
  • Laxmidhar Maharana,
  • M. K. Sharma

摘要

Macrophage polarization has been known as a critical step in balancing inflammatory responses by creating a balanced plasticity between M1 and M2 macrophages, which act as pro-inflammatory and anti-inflammatory mediators, respectively. Histone deacetylases (HDACs) have been shown to play a vital role in polarization, identifying them as possible contributors and therapeutic targets in metabolic diseases, cancer, inflammatory diseases, and other associated conditions. In this regard, isoform-specific HDAC inhibitors (HDACis) can selectively alter macrophage polarization, thereby overcoming the limitations of pan-HDAC inhibitors and offering therapeutic advantages. Moreover, combining HDAC inhibitors with other therapies has emerged as a promising approach, especially in cancer; however, further studies should determine the specificity of HDAC inhibitors as well as address possible problems in optimizing the bioavailability and reducing off-target effects and cytotoxicity to translate these results into practical therapeutic plans for disorders associated with inflammation.